Abbott News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Abbott India Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Abbott from all sources in a single place.

Abbott India Ltd.

24 Dec 2025

Company Update

Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Appointment of Mr. Vivek Mohan (DIN : 00075006) as Additional (Non-Executive) Director with effect from January 1, 2026.

pdf

Abbott India Ltd.

19 Dec 2025

SAST

Abbott India Ltd - 500488 - Closure of Trading Window

BSE India

Closure of Trading Window for the Unaudited Financial Results for the quarter ending on December 31, 2025.

pdf

Abbott India Ltd.

25 Nov 2025

Company Update

Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Change in Senior Management Personnel.

pdf

Abbott India Ltd.

24 Nov 2025

Company Update

Abbott India Ltd - 500488 - Approval Of Central Government For Appointment Of Managing Director

BSE India

Approval of Central Government for appointment of Managing Director

pdf

Abbott India Ltd.

09 Nov 2025

Operational leverage at play

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q2FY26 revenue grew at a modest pace of 7.6% YoY. We believe moderation in growth was mainly due to discontinuation of insulin pens for Human Mixtard, Levemir and Xultophy by Novo Nordisk in India as it prioritises capacity for GLP-1 brands Ozempic and Wegovy.

Abbott India Ltd.'s price crossed below 30Day SMA today

Abbott India Ltd.

08 Nov 2025

Abbott India

Buy: Abbott India Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Decent print driven by growth in some power brands- Revenues grew ~8% YoY to 1757 crore. As per IQVIA, some of the power brands such as Thyronorm (Hormonal), Udiliv (GI), Cremaffin Plus (GI) and Duphalac (GI) witnessed decent growth along with some marketed brands of Novo Nordisk and Abbott Healthcare such as Rybelsus (Semaglutide) and Ryzodeg (Insulin). While Mixtard (Insulin) and Novomix (Anti-Diabetic) registered de-growth during the quarter. EBITDA grew ~14% YoY to 502...

Abbott India Ltd. has an average target of 34729.60 from 5 brokers.

Abbott India Ltd.

07 Nov 2025

Company Update

Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Advertisement

pdf

Abbott India Ltd.

06 Nov 2025

Result

Abbott India Ltd - 500488 - Unaudited Financial Results For The Quarter Ended September 30, 2025.

BSE India

Unaudited financial results for the quarter ended September 30, 2025.

pdf

	Sep 2025	Jun 2025	Sep 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	1827.10	1811.19	1693.15	0.9%	7.9%
Operating Profit Qtr	502.17	445.59	438.96	12.7%	14.4%
Net Profit Qtr	415.27	365.86	358.61	13.5%	15.8%
Earning Per Share Adjusted latest Qtr	195.43	172.18	168.76	13.5%	15.8%

* Standalone data

Detailed Results

Abbott India Ltd.

06 Nov 2025

Board Meeting

Abbott India Ltd - 500488 - Board Meeting Outcome for Outcome Of Board Meeting

BSE India

Outcome of Board Meeting.

pdf

Abbott India Ltd.

29 Oct 2025, 03:32PM

Board Meeting

Abbott India Ltd - 500488 - Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of The …

BSE India

Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025.

pdf

Is Abbott India Ltd. worth buying?

313 Votes:

Buy 79.55%

Sell 10.54%

Hold 9.9%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf